

Peter Johannsen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2647372/publications.pdf>

Version: 2024-02-01

75
papers

5,771
citations

109264

35
h-index

106281

65
g-index

89
all docs

89
docs citations

89
times ranked

8259
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 1 | Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. <i>JAMA Neurology</i> , 2022, 79, 228. | 4.5 | 97 |
| 2 | Six generations of <i>CHMP2B</i> -mediated Frontotemporal Dementia: Clinical features, predictive testing, progression, and survival. <i>Acta Neurologica Scandinavica</i> , 2022, 145, 529-540. | 1.0 | 4 |
| 3 | Replication study of plasma proteins relating to Alzheimer's pathology. <i>Alzheimer's and Dementia</i> , 2021, 17, 1452-1464. | 0.4 | 13 |
| 4 | Middle-Aged Man Concerned about His Family History. , 2021, , 54-58. | | 0 |
| 5 | Cortical Frontoparietal Network Dysfunction in -Frontotemporal Dementia. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 714220. | 1.7 | 0 |
| 6 | Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 1353-1368. | 1.2 | 7 |
| 7 | Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 213-225. | 1.2 | 13 |
| 8 | Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAScan assay. <i>Alzheimer's and Dementia</i> , 2019, 15, 1478-1488. | 0.4 | 46 |
| 9 | Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort. <i>Alzheimer's and Dementia</i> , 2019, 15, 817-827. | 0.4 | 62 |
| 10 | Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum. <i>Alzheimer's and Dementia</i> , 2019, 15, 644-654. | 0.4 | 90 |
| 11 | A metabolite-based machine learning approach to diagnose Alzheimer's type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 933-938. | 1.8 | 70 |
| 12 | Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. <i>Lancet Neurology</i> , The, 2018, 17, 548-558. | 4.9 | 97 |
| 13 | Prevalence of the apolipoprotein E ϵ 4 allele in amyloid β 2 positive subjects across the spectrum of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 913-924. | 0.4 | 58 |
| 14 | Association of Cerebral Amyloid- β 2 Aggregation With Cognitive Functioning in Persons Without Dementia. <i>JAMA Psychiatry</i> , 2018, 75, 84. | 6.0 | 133 |
| 15 | Amyloid- β 2, Tau, and Cognition in Cognitively Normal Older Individuals: Examining the Necessity to Adjust for Biomarker Status in Normative Data. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 193. | 1.7 | 16 |
| 16 | Inflammatory markers of CHMP2B-mediated frontotemporal dementia. <i>Journal of Neuroimmunology</i> , 2018, 324, 136-142. | 1.1 | 10 |
| 17 | Early-Onset Dementia. <i>Alzheimer Disease and Associated Disorders</i> , 2017, 31, 146-151. | 0.6 | 12 |
| 18 | The frequency and influence of dementia risk factors in prodromal Alzheimer's disease. <i>Neurobiology of Aging</i> , 2017, 56, 33-40. | 1.5 | 27 |

| # | ARTICLE | IF | CITATIONS |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 19 | Relation of Odor Identification with Alzheimer's Disease Markers in Cerebrospinal Fluid and Cognition. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 1025-1034. | 1.2 | 33 |
| 20 | Memory Correlates of Alzheimer's Disease Cerebrospinal Fluid Markers: A Longitudinal Cohort Study. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 1119-1128. | 1.2 | 27 |
| 21 | A Danish adaptation of the Boston Naming Test: preliminary norms for older adults and validity in mild Alzheimer's disease. <i>Clinical Neuropsychologist</i> , 2017, 31, 72-87. | 1.5 | 14 |
| 22 | TMEM106B and ApoE polymorphisms in CHMP2B-mediated frontotemporal dementia (FTD-3). <i>Neurobiology of Aging</i> , 2017, 59, 221.e1-221.e7. | 1.5 | 4 |
| 23 | [P2534]: FIRST YEAR DATA FROM THE DANISH NATIONAL DEMENTIA CLINICAL QUALITY DATABASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P846. | 0.4 | 0 |
| 24 | Early microgliosis precedes neuronal loss and behavioural impairment in mice with a frontotemporal dementia-causing CHMP2B mutation. <i>Human Molecular Genetics</i> , 2017, 26, ddx003. | 1.4 | 22 |
| 25 | Moderate-to-High Intensity Physical Exercise in Patients with Alzheimer's Disease: A Randomized Controlled Trial. <i>Journal of Alzheimer's Disease</i> , 2016, 50, 443-453. | 1.2 | 210 |
| 26 | P4122: Prevalence of Vascular Risk Factors in Different Stages of Prodromal Alzheimer's Disease and Its Influence on Cognitive Decline. <i>Alzheimer's and Dementia</i> , 2016, 12, P1059. | 0.4 | 0 |
| 27 | P4184: Shift in Cerebral PET Glucose Metabolism in Frontotemporal Dementia Linked to Chromosome 3 (FTD ϵ 3) from the Presymptomatic to Symptomatic Stage. <i>Alzheimer's and Dementia</i> , 2016, 12, P1090. | 0.4 | 1 |
| 28 | Effect of aerobic exercise on physical performance in patients with Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2016, 12, 1207-1215. | 0.4 | 76 |
| 29 | O1-03-03: Olfactory dysfunction may predict Alzheimer's disease related tau pathology in cerebrospinal fluid (CSF). , 2015, 11, P130-P130. | | 0 |
| 30 | O4-03-01: Early detection of Alzheimer's disease (AD)-related amyloid and tau pathology: A computerized versus a paper-and-pencil memory test. , 2015, 11, P272-P272. | | 0 |
| 31 | Frontotemporal dementia caused by CHMP2B mutation is characterised by neuronal lysosomal storage pathology. <i>Acta Neuropathologica</i> , 2015, 130, 511-523. | 3.9 | 79 |
| 32 | Dementia Diagnosis, Treatment, and Care in Specialist Clinics in Two Scandinavian Countries: A Data Comparison between the Swedish Dementia Registry (SveDem) and the Danish Dementia Registry. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 229-239. | 1.2 | 22 |
| 33 | O3-11-02: Prevalence and diagnostic procedures in early-onset dementia in tertiary referral center patients in denmark, sweden, and the netherlands. , 2015, 11, P244-P245. | | 0 |
| 34 | O5-04-06: Moderate to high-intensity physical exercise in patients with Alzheimer's disease. , 2015, 11, P324-P325. | | 2 |
| 35 | Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1924. | 3.8 | 1,166 |
| 36 | Frequency and Severity of Semantic Deficits in a Consecutive Memory Clinic Cohort. <i>Dementia and Geriatric Cognitive Disorders</i> , 2014, 38, 214-223. | 0.7 | 11 |

| # | ARTICLE | IF | CITATIONS |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 37 | Cognitive impairment in the preclinical stage of dementia in FTD-3 CHMP2B mutation carriers: a longitudinal prospective study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 170-176. | 0.9 | 19 |
| 38 | Corticobasal and ataxia syndromes widen the spectrum of C9ORF72 hexanucleotide expansion disease. <i>Clinical Genetics</i> , 2013, 83, 279-283. | 1.0 | 128 |
| 39 | Preserving Cognition, Quality of Life, Physical Health and Functional Ability in Alzheimer's Disease: The Effect of Physical Exercise (ADEX Trial): Rationale and Design. <i>Neuroepidemiology</i> , 2013, 41, 198-207. | 1.1 | 44 |
| 40 | Brain Energy Metabolism and Blood Flow Differences in Healthy Aging. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2012, 32, 1177-1187. | 2.4 | 145 |
| 41 | Presymptomatic cerebral blood flow changes in CHMP2B mutation carriers of familial frontotemporal dementia (FTD-3), measured with MRI. <i>BMJ Open</i> , 2012, 2, e000368. | 0.8 | 13 |
| 42 | EFNS task force: the use of neuroimaging in the diagnosis of dementia. <i>European Journal of Neurology</i> , 2012, 19, 1487-1501. | 1.7 | 112 |
| 43 | Reversal of pathology in CHMP2B-mediated frontotemporal dementia patient cells using RNA interference. <i>Journal of Gene Medicine</i> , 2012, 14, 521-529. | 1.4 | 14 |
| 44 | Development of a dementia assessment quality database. <i>Aging and Mental Health</i> , 2011, 15, 40-46. | 1.5 | 14 |
| 45 | Frontotemporal Dementia Caused by CHMP2B Mutations. <i>Current Alzheimer Research</i> , 2011, 8, 246-251. | 0.7 | 85 |
| 46 | FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. <i>Acta Neuropathologica</i> , 2010, 120, 33-41. | 3.9 | 222 |
| 47 | Disruption of endocytic trafficking in frontotemporal dementia with CHMP2B mutations. <i>Human Molecular Genetics</i> , 2010, 19, 2228-2238. | 1.4 | 163 |
| 48 | Presymptomatic Generalized Brain Atrophy in Frontotemporal Dementia Caused by CHMP2B Mutation. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009, 27, 182-186. | 0.7 | 17 |
| 49 | Validation of Alzheimer's disease CSF and plasma biological markers: The multicentre reliability study of the pilot European Alzheimer's Disease Neuroimaging Initiative (E-ADNI). <i>Experimental Gerontology</i> , 2009, 44, 579-585. | 1.2 | 60 |
| 50 | The diagnostic efficiency of biomarkers in sporadic Creutzfeldt-Jakob disease compared to Alzheimer's disease. <i>Neurobiology of Aging</i> , 2009, 30, 1834-1841. | 1.5 | 46 |
| 51 | Cortical volumes and atrophy rates in FTD-3 CHMP2B mutation carriers and related non-carriers. <i>NeuroImage</i> , 2009, 45, 713-721. | 2.1 | 28 |
| 52 | Validation of the Danish Addenbrooke's Cognitive Examination as a Screening Test in a Memory Clinic. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009, 27, 361-365. | 0.7 | 42 |
| 53 | The pilot European Alzheimer's Disease Neuroimaging Initiative of the European Alzheimer's Disease Consortium. , 2008, 4, 255-264. | | 39 |
| 54 | Usability of Cerebrospinal Fluid Biomarkers in a Tertiary Memory Clinic. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 25, 553-558. | 0.7 | 11 |

| # | ARTICLE | IF | CITATIONS |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 55 | A Reassessment of the Neuropathology of Frontotemporal Dementia Linked to Chromosome 3. <i>Journal of Neuropathology and Experimental Neurology</i> , 2007, 66, 884-891. | 0.9 | 118 |
| 56 | Assessing Therapeutic Efficacy in a Progressive Disease. <i>CNS Drugs</i> , 2006, 20, 311-325. | 2.7 | 57 |
| 57 | Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. <i>Nature Genetics</i> , 2005, 37, 806-808. | 9.4 | 752 |
| 58 | Cerebral Metabolic Response to Low Blood Flow: Possible Role of Cytochrome Oxidase Inhibition. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2005, 25, 1183-1196. | 2.4 | 90 |
| 59 | Frontotemporal Dementia Linked to Chromosome 3. <i>Dementia and Geriatric Cognitive Disorders</i> , 2004, 17, 274-276. | 0.7 | 8 |
| 60 | Long-Term Cholinesterase Inhibitor Treatment of Alzheimer's Disease. <i>CNS Drugs</i> , 2004, 18, 757-768. | 2.7 | 53 |
| 61 | Cerebral functional anatomy of voluntary contractions of ankle muscles in man. <i>Journal of Physiology</i> , 2001, 535, 397-406. | 1.3 | 35 |
| 62 | Dementia with Impaired Temporal Glucose Metabolism in Late-Onset Metachromatic Leukodystrophy. <i>Dementia and Geriatric Cognitive Disorders</i> , 2001, 12, 85-88. | 0.7 | 18 |
| 63 | Cerebral activation during bicycle movements in man. <i>Experimental Brain Research</i> , 2000, 135, 66-72. | 0.7 | 177 |
| 64 | Cortical Centres Underlying Auditory Temporal Processing in Humans: A PET Study. <i>International Journal of Audiology</i> , 2000, 39, 30-37. | 0.9 | 21 |
| 65 | Stimulus-dependent central processing of auditory stimuli: A PET study. <i>Scandinavian Audiology</i> , 1999, 28, 161-169. | 0.5 | 57 |
| 66 | Ageing and dementia.: Edited by K. Jellinger, F. Fazekas and M. Windisch. Published by Springer-Verlag, Vienna, 1998. 406 pp. Price US\$ 159; DM. <i>Acta Psychiatrica Scandinavica</i> , 1999, 99, 82-82. | 2.2 | 0 |
| 67 | Positron emission tomography of cortical centers of tinnitus. <i>Hearing Research</i> , 1999, 134, 133-144. | 0.9 | 211 |
| 68 | Cortical Responses to Sustained and Divided Attention in Alzheimer's Disease. <i>NeuroImage</i> , 1999, 10, 269-281. | 2.1 | 71 |
| 69 | Activation of Human Extrageniculostriate Pathways after Damage to Area V1. <i>NeuroImage</i> , 1999, 9, 97-107. | 2.1 | 44 |
| 70 | Cerebral Blood Flow Measurements by Magnetic Resonance Imaging Bolus Tracking: Comparison with [15O]H ₂ O Positron Emission Tomography in Humans. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1998, 18, 935-940. | 2.4 | 212 |
| 71 | Cerebral blood-flow changes evoked by two levels of painful heat stimulation: A positron emission tomography study in humans. <i>European Journal of Pain</i> , 1998, 2, 95-106. | 1.4 | 29 |
| 72 | Origin of Human Motor Readiness Field Linked to Left Middle Frontal Gyru by MEG and PET. <i>NeuroImage</i> , 1998, 8, 214-220. | 2.1 | 75 |

| # | ARTICLE | IF | CITATIONS |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 73 | Cortical Sites of Sustained and Divided Attention in Normal Elderly Humans. <i>NeuroImage</i> , 1997, 6, 145-155. | 2.1 | 74 |
| 74 | Epilepsy in Down syndrome—prevalence in three age groups. <i>Seizure: the Journal of the British Epilepsy Association</i> , 1996, 5, 121-125. | 0.9 | 30 |
| 75 | The Prevalence of Dementia in Down Syndrome. <i>Dementia and Geriatric Cognitive Disorders</i> , 1996, 7, 221-225. | 0.7 | 12 |